The financing follows a strategic shift for Orum, which shelved its original lead program and is now pursuing a potential ...

The fresh capital provides another shot for Moderna's candidate against bird flu, which earlier this year lost its government ...

Analysts see little effect on the bottom lines of biopharma companies, as they stand to stave off tariff pressure and receive ...

The results position Takeda, which acquired its therapy in one of the industry’s larger single-drug acquisitions, to ...

The startup’s filing comes during a broader biotech recovery that’s made some industry watchers optimistic IPOs could rebound ...

The FDA placed the hold after researchers recorded a “higher than anticipated” incidence of deaths in a study testing “I-DXd” ...

The company’s valuation, which surged past $40 billion this year, fell by almost a fifth on a dimmer outlook for its closely ...

Orforglipron helped keep weight down when used after initial therapy with an injectable, a new treatment strategy that could ...

The clearance brings an oral form of Novo’s Wegovy to market ahead of Lilly’s rival medication and kicks off the next phase ...

Analysts said the deal makes sense for BioMarin, as it offers a late-stage clinical asset as well as two marketed therapies ...

The Belgian biotech is still on the hunt for partners after reporting that its drug succeeded against an inflammatory skin ...

The overall leadership outlook was positive in a recent survey but varied between executives in the U.S. and those overseas.